SCHEMBL6433202

SCHEMBL6433202

CCN(CCO)CCCCN(C)c1ccnc2cc(O)ccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 1/20 0.50
CHRM2 P08172 2/20 0.48
CHRM4 P08173 2/20 0.48
CHRM5 P08912 2/20 0.48
ADRA2A P08913 2/20 0.48
CHRM1 P11229 2/20 0.48
ADRA2B P18089 2/20 0.48
ADRA2C P18825 2/20 0.48
CHRM3 P20309 2/20 0.48
KCNH2 Q12809 2/20 0.48
TMEM97 Q5BJF2 2/20 0.48
SIGMAR1 Q99720 2/20 0.48
ACE2 Q9BYF1 2/20 0.48
LMNA P02545 2/20 0.48
ADRA1D P25100 1/20 0.48
CGAS Q8N884 1/20 0.48
TLR9 Q9NR96 1/20 0.48
TLR7 Q9NYK1 1/20 0.48
KIT P10721 2/20 0.39
SYK P43405 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3454269 0.93 CHRM2 (0.43) CDK1CHRM2CHRM4CHRM5ADRA2A
SCHEMBL5074576 0.87 CDK1 (0.49) CDK1CHRM2CHRM4CHRM5ADRA2A
SCHEMBL3229048 0.87 CDK1 (0.66) CDK1CHRM2CHRM4CHRM5ADRA2A
SCHEMBL1695270 0.85 CDK1 (0.47) CDK1CHRM2CHRM4CHRM5ADRA2A
SCHEMBL1695377 0.84 HRH3 (0.54) CDK1CHRM2CHRM4CHRM5ADRA2A
SCHEMBL710402 0.80 CDK1 (0.74) CDK1CHRM2CHRM4CHRM5ADRA2A
SCHEMBL1695397 0.78 TMEM97 (0.51) CDK1CHRM2CHRM4CHRM5ADRA2A
SCHEMBL1695452 0.78 CHRM2 (0.43) CDK1CHRM2CHRM4CHRM5ADRA2A
SCHEMBL3454549 0.78 KCNH2 (0.60) CDK1CHRM2CHRM4CHRM5ADRA2A
SCHEMBL1550842 0.78 KDM4E (0.44) CDK1CHRM2CHRM4CHRM5ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2694086-A1 MHC ENGAGEMENT AND CLIP MODULATION FOR THE TREATMENT OF DISEASE The Texas A&M University System (US) 2014-02-12 EP claimed
WO-2012138708-A1 MHC ENGAGEMENT AND CLIP MODULATION FOR THE TREATMENT OF DISEASE THE TEXAS A&M UNIVERSITY SYSTEM (US) 2012-10-11 WO claimed
WO-2012135632-A2 METHODS OF TREATING A SUBJECT HAVING BEEN EXPOSED TO A CATASTROPHIC EVENT THE TEXAS A&M UNIVERSITY SYSTEM (US) 2012-10-04 WO claimed
EP-1261340-A4 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE ALPHA RES GROUP LLC (US) 2005-05-04 EP claimed
JP-2004500331-A 2004-01-08 JP claimed
EP-1261340-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE Alpha Research Group, LLC (US) 2002-12-04 EP claimed
WO-2001003649-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE ALPHA RESEARCH GROUP, LLC (US) 2001-01-18 WO claimed
WO-2026102297-A1 ANTIBODY OLIGONUCLEOTIDE CONJUGATES FOR TREATING DISEASE Fulcrum Therapeutics, Inc. (US) 2026-05-15 WO disclosed
WO-2026102333-A1 METHODS OF TREATING CARDIOMYOPATHY USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES Atrium Therapeutics, Inc. (US) 2026-05-15 WO disclosed
EP-4735602-A2 COMPOSITIONS AND METHODS OF USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES ABSTRACT Atrium Therapeutics, Inc. (US) 2026-05-06 EP disclosed
WO-2025006639-A2 COMPOSITIONS AND METHODS OF USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES ABSTRACT AVIDITY BIOSCIENCES, INC. (US) 2025-01-02 WO disclosed
EP-4401792-A1 COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY Avidity Biosciences, Inc. (US) 2024-07-24 EP disclosed
WO-2023043953-A1 COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY AVIDITY BIOSCIENCES, INC. (US) 2023-03-23 WO disclosed
WO-2020132584-A1 ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF AVIDITY BIOSCIENCES, INC. (US) 2020-06-25 WO disclosed
WO-2017165489-A1 ANTIVIRAL AGENTS FOR TREATING ZIKA AND DENGUE VIRUS INFECTIONS EMORY UNIVERSITY (US) 2017-09-28 WO disclosed
WO-2012163814-A1 CANCER TREATMENT BY COMBINING DNA MOLECULES MIMICKING DOUBLE STRAND BREAKS WITH HYPERTHERMIA INSTITUT CURIE (FR) 2012-12-06 WO disclosed
WO-2012135632-A2 METHODS OF TREATING A SUBJECT HAVING BEEN EXPOSED TO A CATASTROPHIC EVENT THE TEXAS A&M UNIVERSITY SYSTEM (US) 2012-10-04 WO disclosed
EP-1261340-A4 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE ALPHA RES GROUP LLC (US) 2005-05-04 EP disclosed
EP-1261340-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE Alpha Research Group, LLC (US) 2002-12-04 EP disclosed
WO-2001003649-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE ALPHA RESEARCH GROUP, LLC (US) 2001-01-18 WO disclosed